Figure 6. Exosomal SOX2-OT contributes to the progression of ovarian cancer by miR-181b-5p/ SCD1 axis in vitro. (A–E) The TOV-21G and SKOV-3 cells were treated with control shRNA or SOX2-OT shRNA, co-treated with SOX2-OT shRNA and miR-181b-5p inhibitor or pcDNA3.1-SCD1. (A, B) The cell viability was measured by MTT assays in the cells. (C, D) The cell apoptosis was analyzed by flow cytometry analysis in the cells. (E) The expression of Bcl-2, Bax, cleaved-caspase3, and caspase3 was measured by Western blot analysis in the cell. Data are presented as mean ± SD. Statistic significant differences were indicated: ** P < 0.01.